Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients

Li-chun Ho1,2, Chung-Jen Yen2, Chia-Ter Chao2, Chih-Kang Chiang1,3, Jenq-Wen Huang2 & Kuan-Yu Hung2

Factors associated with increased visceral fat area (VFA) have been well documented in the general population but rarely explored in nondiabetic individuals on peritoneal dialysis (PD). As glycosylated hemoglobin (HbA1c) is positively correlated with VFA in diabetic patients, we hypothesized that the same correlation would exist in nondiabetic PD patients. We enrolled 105 nondiabetic patients who had undergone chronic PD for more than 3 months. Each subject underwent an abdominal computed tomography (CT) scan, and the umbilicus cut was analyzed for VFA. VFA values, corrected for body mass index and subjected to natural logarithm transformations, were examined to determine whether they were correlated with HbA1c and other parameters. PD dialysates prescribed at the time of enrollment were recorded to calculate glucose load. We found that when 105 nondiabetic PD patients were classified according to tertiles of HbA1c, higher HbA1c was associated with larger VFA. Multiple linear regression analysis revealed that HbA1c was an independent determinant of VFA, while glucose load and other PD-specific factors were not. In summary, HbA1c, but not PD-related glucose load, was positively correlated with VFA in nondiabetic PD patients, suggesting clinical utility of HbA1c in the PD population.

Robust evidence has suggested a causative role for visceral obesity in insulin resistance, atherogenic dyslipidemia, and adverse cardiovascular events. Visceral adiposity has also been associated with increased cardiovascular risk in hemodialysis (HD) and peritoneal dialysis (PD) patients, and this association remained after adjusting for the confounding effects of diabetes mellitus (DM). Etiologies contributing to visceral fat accumulation include old age, male sex, Asian origin, chronic stress, saturated fat intake, and fructose consumption. Antihypertensive medicines may also modulate body fat distribution, as renin-angiotensin system (RAS) blockade reduces visceral fat accumulation, while nonvasodilating beta blockers tend to induce unfavorable cardiometabolic effects.

The PD population is unique with respect to research involving visceral adiposity because of two characteristics. First, the infusion of glucose-based PD solution results in an extra 100–200 g glucose load per day, which could explain the greater increase in visceral fat area (VFA) observed in PD patients relative to HD patients. Second, waist circumference may not be a trustworthy indicator of VFA, as the abdomen becomes distended due to accumulation of PD fluid. Although computed tomography (CT) is a reliable means of assessing VFA in PD patients, it is too expensive to be used routinely in clinical settings. A surrogate marker indicating the degree of visceral adiposity present in PD patients is therefore of great use.

1Division of Nephrology, Department of Internal Medicine, I-Shou University, E-DA Road, Kaohsiung, Taiwan. 2Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei. 3Department of Internal Medicine, Jin-Shan branch, National Taiwan University Hospital and College of Medicine, New Taipei City, Taiwan. Correspondence and requests for materials should be addressed to J.-W.H. (email: 007378@ntuh.gov.tw)
Glycosylated hemoglobin (HbA1c) has been shown to be positively correlated with VFA in patients with type 2 DM. Whether this correlation exists in nondiabetic patients is unclear, but several studies have found that elevated HbA1c levels, even those that did not reach the criteria for DM diagnosis, predicted mortality in general nondiabetic populations as well as nondiabetic PD patients. Given the detrimental impact of visceral adiposity on PD patients, it is quite reasonable to assume that the adverse effects of HbA1c observed in the nondiabetic PD population may be derived from its link to visceral obesity.

The aim of this study was to examine the association between VFA and HbA1c in nondiabetic PD patients. We intended to prove the association by showing a dose-dependent effect of VFA in patients grouped according to HbA1c tertile, and a statistically significant result in a correlation test for HbA1c and VFA. Furthermore, the independency of HbA1c as a determinant for VFA was tested in a linear model adjusting for the clinical parameters related to visceral adiposity.

Methods
Study design. Nondiabetic dialysis patients who were older than 20 years of age and had undergone chronic PD for more than 3 months were enrolled in the study in 2009. The definition of nondiabetic status in this study was HbA1c ≤ 6.4% without a history of anti-diabetic treatment. Pregnant women and patients who had undergone CT scan during the preceding 6 months were excluded from study participation. After providing informed consent, each patient underwent an abdominal CT scan and blood sample collection. Patients refrained from eating for 6h prior to undergoing phlebotomy. The blood samples were immediately centrifuged at 3,000 rpm and 4°C. The plasma samples were frozen at −80°C until analysis.

Ethical considerations. This study was approved by the ethics committee of National Taiwan University hospital in NTUH-REC No. 200808062R and NTUH-REC No. 201104032RC. The study was carried out in accordance with the approved guidelines. Patients provided written informed consent prior to participating in the study.

Assessment of abdominal fat using computed tomography. Imaging was performed using a 64-MDCT scanner (LightSpeed VCT; GE Healthcare, Milwaukee, WI), and the umbilicus cut was analyzed for VFA. Image analysis software (ImageJ, version 1.45; National Institutes of Health, Bethesda, MD) was used at an attenuation range of −50 to −250 Hounsfield units to quantify abdominal adipose tissue areas in cm². Subcutaneous fat area (SFA) was clearly visible and defined as extraperitoneal fat between skin and muscle. Intra-abdominal tissue at the same density as SFA was defined as VFA. The sum of SFA and VFA represented the total fat area (TFA). The images were reviewed by radiologists who were unaware of the clinical characteristics of the PD patients. These indicators for fat area were all corrected for BMI (units, cm²/[kg/m²]), because fat area is related to body size.

HbA1c and other clinical characteristics. Blood HbA1c level of each PD patient was measured by Boronate affinity chromatography as described in our previous report. Other clinical data were obtained via anthropometric measurement, biochemical study for the plasma samples, and reviewing the medical records for PD treatment. These clinical characteristics were classified into 5 types: (1) Demographic and anthropometric factors related with visceral adiposity, including age, sex, BMI, and lean body mass estimated by creatinine kinetics. (2) Factors associated with glucose metabolism and visceral fat accumulation, including fasting plasma glucose, plasma insulin level, and insulin resistance represented by homeostasis model assessment (HOMAIR). (3) PD-specific factors included PD duration, peritoneal urea clearance (Kt/V), residual renal function, and the results of peritoneal equilibration test. In addition, records detailing the dialysate that was prescribed to each PD patient in 2009 were used to calculate glucose load according to a method described previously. Glucose load 1 represented the average glucose concentration in total PD fluid including Extraneal and Nutrineal. Glucose load 2 represented the average glucose concentration of glucose-based dialysate alone. (4) Patients who had received RAS blockades or beta blockades for more than 3 months at the time of enrolment were recorded as RAS or beta blockade users. (5) Cardiovascular risk-related factors in PD patients included nutrition markers (i.e. albumin, normalized protein catabolic rates [nPCR], and creatinine), inflammatory markers (i.e. C-reactive protein [CRP]), lipid metabolic factors (i.e. cholesterol [CHO], triglyceride [TG], low density lipoprotein [LDL], and high density lipoprotein [HDL]), and atherogenic indices (AIs). Two AIs were derived from the lipid profile according to the following equations: AI1 = log (TG/HDL-C) and AI2 = non-HDL cholesterol/HDL = (T-CHO-HDL)/HDL.

Statistical analysis. All continuous variables were reported as means ± SDs (with 95% confidence intervals as appropriate), and all categorical variables were reported as frequencies or percentages. Comparison between two groups was performed using the two-sided Student t test whereas comparison among three or more groups (e.g. groups according to HbA1c tertile) was using one way analysis of variance (ANOVA). The differences in sex distribution were tested using χ² analysis. The relationships between variables were assessed using Pearson’s correlation coefficients. The independent determinants of the variables were examined via multiple linear regression analysis. Variables were selected via a stepwise analysis.
procedure with backward selection. A p value of 0.1 was used as the limit for entry into the model. For all statistical testing, p values of < 0.05 were considered significant unless otherwise specified. Statistical analyses were conducted using SPSS 13.0 for Windows (SPSS Inc., IL, USA).

Results
Comparing VFA among groups classified according to HbA1c tertiles. A total of 138 nondiabetic PD patients who met the study criteria underwent abdominal CT. Of these patients, 105 underwent blood sample collection and analysis. The patients were classified into 3 groups according to HbA1C tertiles: Group 1: HbA1c ≤ 5.1% (N = 36), Group 2: HbA1c = 5.2–5.5% (N = 34), and Group 3: HbA1c = 5.6–6.4% (N = 35). Higher HbA1c was associated with larger TFA (P = 0.013) and VFA (P = 0.002) in nondiabetic PD patients, while the differences in SFA between groups did not reach statistical significance (P = 0.17) (Fig. 1). Besides the increased in VFA, patients with a higher HbA1c level also tended to be older (P = 0.052) and demonstrated a trend toward impaired glucose metabolism (higher fasting glucose [P = 0.001] and HOMA IR [P = 0.001]) (Table 1). In contrast, PD-specific factors, including PD duration and PD glucose load, were unrelated to HbA1c tertile (Table 1). The only exception was peritoneal urea clearance (peritoneal Kt/V), which reversely correlated with HbA1c tertile (P = 0.048). Only two cardiovascular risk-related factors, creatinine (P = 0.043) and CRP (P = 0.041), were associated with HbA1c tertile. Interestingly, it was the group with the middle HbA1c tertile had the highest serum creatinine and the lowest CRP level, suggesting more muscle mass and less inflammatory status in this group than in the other two groups (Table 1).

Correlations between HbA1c, VFA and other clinical parameters. The associations between HbA1c and VFA and other variables were analyzed using Pearson correlation coefficients. As VFA and CRP were not normally distributed, we used the natural logarithm transformations of two variables. Table 2 showed that HbA1c and lnVFA were positively correlated with each other (p < 0.001) and age (p = 0.01 for HbA1c, p < 0.001 for lnVFA), BMI (p = 0.02 for HbA1c, p < 0.001 for lnVFA), glucose metabolic factors like HOMA IR (p < 0.001 for both HbA1c and lnVFA) and serum insulin level (p < 0.001 for both HbA1c and lnVFA), and negatively correlated with percentage of lean body mass (p = 0.01 for HbA1c, p < 0.001 for lnVFA). PD glucose load and other PD-specific factors were not significantly correlated with HbA1c or lnVFA except that HbA1c was negatively correlated with peritoneal Kt/V (p = 0.02). As for cardiovascular risk-related factors, both HbA1c and lnVFA were positively correlated with lnCRP (p = 0.01 for HbA1c, p < 0.001 for lnVFA) and AI1 (p = 0.03 for HbA1c, p < 0.001 for lnVFA), whereas
only lnVFA but not HbA1c was positively correlated with nutritional markers albumin (p = 0.02), nPCR (p = 0.03), and atherogenic marker A12 (p < 0.001).

The effects of RAS and beta blockades on HbA1c and VFA. RAS and beta blockades may affect glucose and lipid metabolism and consequently alter HbA1c and VFA. Figure 2 shows that RAS- and beta-blockade users displayed similar HbA1c levels and HOMAIR to nonusers (RAS-blockade users vs. nonusers, HbA1c: 5.3 ± 0.4% vs. 5.3 ± 0.5%, p = 0.52, HOMAIR: 3.33 ± 1.88 vs. 3.11 ± 1.80, p = 0.55; beta-blockade users vs. nonusers, HbA1c: 5.3 ± 0.4% vs. 5.3 ± 0.5%, p = 0.65, HOMAIR: 3.56 ± 1.88 vs. 2.69 ± 1.65, p = 0.17). However, RAS and beta blockades appeared to exert an impact on VFA in our patients. Patients taking RAS blockades showed a trend toward lower VFA relative to those who did not take RAS blockades (346 ± 184 mm²/kg/m² vs. 410 ± 192 mm²/kg/m², p = 0.09), while the patients taking beta blockades exhibited significantly higher VFA relative to those who did not take beta blockades (405 ± 199 mm²/kg/m² vs. 330 ± 167 mm²/kg/m², p = 0.05).

Independent determinants of VFA. The independent determinants of lnVFA were analyzed with multiple linear regression. All available variables were introduced into the regression model and were selected by a stepwise procedure. Table 3 listed only the variables with sufficient significance to remain in the model. HbA1c was positively and independently associated with lnVFA (p = 0.005). BMI remained an independent predictor of lnVFA (p = 0.002), even though VFA had been corrected for BMI. Age (p = 0.045) and A11 (p = 0.002) were positively associated with lnVFA while RAS blockade use (p = 0.046) and serum creatinine levels (p = 0.022) were negatively associated with lnVFA in nondiabetic PD patients (R² = 0.484, Table 3).

| Glycosylated hemoglobin category | ≤5.1% | 5.2-5.5% | 5.6-6.4% |
|----------------------------------|-------|----------|----------|
| TFA (mm²/Kg/m²)*                | 794 ± 312 | 913 ± 372 | 1052 ± 399 |
| SFA (mm²/Kg/m²)                 | 497 ± 205 | 532 ± 223 | 598 ± 260  |
| VFA (mm²/Kg/m²)*               | 297 ± 172 | 380 ± 183 | 454 ± 186  |
| Sex (men/women)                | 10/26 | 15/19 | 14/21 |
| Age (years)*                   | 48 ± 16 | 52 ± 13 | 54 ± 10  |
| BMI (kg/m²)                    | 21.7 ± 2.8 | 22.9 ± 3.2 | 23.1 ± 3.0 |
| Glucose (mg/dL)*               | 94 ± 15 | 94 ± 16 | 108 ± 27  |
| HOMAIR*                        | 2.70 ± 1.75 | 2.82 ± 1.25 | 4.17 ± 2.06 |
| PD Vintage (months)            | 55 ± 45 | 48 ± 46 | 47 ± 40  |
| Peritoneal Ktx/V**             | 2.05 ± 0.46 | 1.92 ± 0.34 | 1.83 ± 0.25 |
| Renal Ktx/V                    | 0.20 ± 0.30 | 0.16 ± 0.28 | 0.18 ± 0.24 |
| Glucose load 1 (g/dL)          | 1.67 ± 0.27 | 1.69 ± 0.26 | 1.66 ± 0.32 |
| Glucose load 2 (g/dL)          | 1.85 ± 0.33 | 1.84 ± 0.31 | 1.86 ± 0.32 |
| nPCR (g/Kg/day)                | 1.02 ± 0.16 | 0.93 ± 0.16 | 0.96 ± 0.22 |
| Albumin (g/dL)                 | 4.0 ± 0.4 | 4.1 ± 0.4 | 4.1 ± 0.3  |
| Creatinine (mg/dL)*            | 10.9 ± 2.6 | 12.3 ± 3.1 | 11.0 ± 2.7  |
| CRP (mg/dL)*                   | 0.84 ± 1.38 | 0.41 ± 0.57 | 1.69 ± 3.35 |
| Cholesterol (mg/dL)            | 202 ± 56 | 194 ± 39 | 205 ± 55  |
| Triglyceride (mg/dL)           | 170 ± 101 | 179 ± 157 | 245 ± 253  |
| A11                             | 0.52 ± 0.35 | 0.53 ± 0.37 | 0.66 ± 0.34 |
| A12                             | 3.76 ± 1.36 | 3.83 ± 1.38 | 4.01 ± 1.62 |

Table 1. Clinical characteristics of the three peritoneal dialysis groups classified according to HbA1C tertiles. Differences among the 3 groups were analyzed using ANOVA, except that sex was analyzed using χ² test. *P ≤ 0.05. TFA: total fat area; SFA: subcutaneous fat area; VFA: visceral fat area; BMI: body mass index; HOMAIR: homeostasis model assessment-insulin resistance; PD: peritoneal dialysis; Ktx/V: urea clearance; nPCR: normalized protein catabolic rate; CRP: C-reactive protein; A11: atherogenic index 1; A12: atherogenic index 2.
Discussion
This cross-sectional study aimed to reveal the determinants of VFA in a nondiabetic PD population. Our results showed a positive and independent association between HbA1c and VFA, while PD-specific factors, glucose load, and peritoneal Kt/V were not significantly correlated with VFA.

Linking HbA1c to VFA may expand the clinical utility of HbA1c for PD patients. A positive correlation between HbA1c and VFA has been shown in nondiabetic, nondiagnosis populations 19,26,27, and the present study found the same correlation in nondiabetic PD patients. Given the harmful effects of visceral fat accumulation1, the link between HbA1c and VFA may explain the predictive power of HbA1c with respect to mortality and adverse outcomes in general nondiabetic populations 9,10,28 as well as nondiabetic PD patients11,29. Our results were not only compatible with our previous finding that body composition affects PD patients’ survival 30 but also suggested that, in nondiabetic PD patients, HbA1c is a potential surrogate marker for VFA, prompting physicians to initiate early action against visceral obesity.

Among factors associated with VFA, several were also correlated with HbA1c (Table 2). Old age and high BMI have been acknowledged as etiologies of visceral fat accumulation1, and the adverse influence of visceral adiposity on glucose and lipid metabolism could contribute to positive correlations between VFA and insulin resistance (HOMA IR), HbA1c, and atherogenic risk (AI). Although lower VFA and HbA1c generally mean less obesity and healthier nutritional status, it is interesting that the highest creatinine (indicating muscle mass) and lowest CRP were not observed in patients with the lowest VFA and HbA1c but were present in those with HbA1c in the second tertile (Table 1). This result was compatible with findings from previous studies in which HbA1c of less than 5.1% was associated with increased mortality in a general nondiabetic population and nondiabetic PD patients9,11. The J-shape association curve is generally referred to as protein-energy wasting, a phenomenon in which malnutrition is associated with inflammation and survival disadvantages12. Nevertheless, visceral adiposity is still an important therapeutic target, and some studies have suggested the use of RAS blockades or avoidance of beta blockades to decrease visceral fat accumulation3,3. The benefits of RAS blockades and disadvantages of beta blockades with respect to VFA were also suggested in our study subjects (Fig. 2, Table 3), although a clear cause-effect relationship could not be confirmed in a cross-sectional study like the present one. Despite the above-mentioned complex associations between HbA1c and multiple risk factors, HbA1c remained independently associated with VFA in the multiple linear regression model (Table 3), implying a fundamental role for VFA in inducing insulin resistance in nondiabetic PD patients.

The current study did not find an association between VFA and PD-related glucose load. In our previous study, involving both diabetic and nondiabetic PD patients, high glucose load was associated with poor survival30. As PD patients showed greater longitudinal increase in visceral fat and poorer glucose metabolism relative to HD patients3,3, our preliminary hypothesis was that glucose load related to PD fluid would affect survival by inducing visceral fat accumulation and aggravating insulin resistance.

Table 2. Correlations between HbA1c and VFA and other clinical parameters. The correlation was assessed using Pearson’s correlation coefficients. VFA: visceral fat area; HOMA IR: homeostasis model assessment-insulin resistance; BMI: body mass index; LBM: lean body mass; PD: peritoneal dialysis; Kt/V: urea clearance; nPCR: normalized protein catabolic rate; CRP: C-reactive protein; AI1: atherogenic index 1; AI2: atherogenic index 2.
Figure 2. The effects of RAS and beta blockades on insulin resistance and visceral fat. Patients who did not take RAS blockades: n = 50; patients taking RAS blockades: n = 55; patients who did not take beta blockades: n = 45; patients taking beta blockades: n = 60. Comparisons between the users and nonusers were performed using Student t test. HbA1c: glycosylated hemoglobin; HOMA_{IR}: homeostasis model assessment-insulin resistance; VFA: visceral fat area.
Table 3. Independent determinants of visceral fat in nondiabetic peritoneal dialysis patients analyzed via multiple linear regression. R² = 0.484. AI: atherogenic index, BMI: body mass index, CRP: C-reactive protein, RAS: rennin-angiotensin system.

|                        | B ± SE   | 95%CI       | P       |
|------------------------|----------|-------------|---------|
| HbA1c                  | 0.330 ± 0.114 | 0.103–0.557 | 0.005   |
| BMI                    | 0.050 ± 0.016 | 0.019–0.082 | 0.002   |
| Age                    | 0.008 ± 0.004 | 0.000–0.016 | 0.045   |
| LnCRP                  | 0.052 ± 0.031 | −0.010–0.114 | 0.096   |
| AII                    | 0.428 ± 0.131 | 0.167–0.689 | 0.002   |
| RAS blockade           | −0.184 ± 0.091 | −0.364–0.003 | 0.046   |
| Creatinine             | −0.040 ± 0.017 | −0.075–0.006 | 0.022   |
| Constant               | 2.738 ± 0.630 | 1.488–3.989 | <0.001  |

However, our data showed that neither glucose load nor PD duration was associated with VFA or HbA1c (Tables 1 and 2). PD transport characteristics, which constitute a variable that is highly correlated with glucose load, were also analyzed in the linear regression analysis but were not relevant with respect to VFA (data not shown). It is probable that, in nondiabetic patients, glucose load did not exceed the metabolic capacity to handle it; therefore, it did not have a marked effect on visceral adiposity.

There were some limitations to this study. It was cross-sectional in design; therefore, prospective changes in VFA and HbA1c were unknown. All the participants were Asian origin, which has been acknowledged as a risk factor for visceral fat accumulation; thus the generalizability of our conclusions may be limited. Saturated fat intake and fructose consumption were not recorded for our subjects; however, the metabolic consequences of these nutrients (atherogenic lipid profile and insulin resistance) were well analyzed in our study. Several conditions present in PD patients may disturb the accuracy of HbA1c (e.g., iron deficiency, vitamin B12 deficiency, and uremia)\(^{33}\). Although we did not adjust for these disturbing factors, a previous study identified HbA1c as a reliable index of glycemic control in diabetic PD patients\(^{16}\); therefore, the reliability of HbA1c in nondiabetic PD patients may be acceptable.

In summary, our study showed that HbA1c and VFA were independently and positively associated with each other in nondiabetic PD patients. These results suggested clinical utility of HbA1c as a surrogate marker for VFA in nondiabetic PD patients and highlighted the need for further research to study the prognostic value of HbA1c in PD populations.

References
1. Tchernof, A. & Despres, J. P. Pathophysiology of human visceral obesity: an update. Physiol. Rev. 93, 359–404 (2013).
2. Yamauchi, T. et al. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. Nephrol. Dial. Transplant. 18, 1842–1847 (2003).
3. Wu, C. K. et al. Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients. PLoS one 8, e62722 (2013).
4. Chujo, D. et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens. Res. 30, 1205–1210 (2007).
5. Bakris, G. L. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292, 2227–2236 (2004).
6. Holmes, C. J. Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution. J. Diabetes Sci. Technol. 3, 1472–1480 (2009).
7. Pellicano, R., Strauss, B. J., Polkinghorne, K. R. & Kerr, P. G. Longitudinal body composition changes due to dialysis. Clin. J. Am. Soc. Nephrol. 6, 1668–1675 (2011).
8. Gastaldelli, A. et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J. Clin. Endocrinol. Metab. 87, 5098–5103 (2002).
9. Selvin, E. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362, 800–811 (2010).
10. Barr, E. L. et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 52, 415–424 (2009).
11. Chen, K. H. et al. Glycated hemoglobin predicts mortality in nondiabetic patients receiving chronic peritoneal dialysis. Am. J. Nephrol. 32, 567–574 (2010).
12. Lu, Q. et al. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J. Ren. Nutr. 18, 495–502 (2008).
13. Lee, M. J. et al. Visceral fat thickness is associated with carotid atherosclerosis in peritoneal dialysis patients. Obesity 20, 1301–1307 (2012).
14. Gotoh, H. et al. Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrol. Dial. Transplant. 24, 3474–3480 (2009).
15. Odamaki, M. et al. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol. Dial. Transplant. 14, 2427–2432 (1999).
16. Lee, S. Y. et al. Glycosylated hemoglobin and albumin-corrected fructosamine are good indicators for glycemic control in peritoneal dialysis patients. PLoS one 8, e57762 (2013).
17. Keshaviah, P. R. et al. Lean body mass estimation by creatinine kinetics. J. Am. Soc. Nephrol. 4, 1475–1485 (1994).
18. Haffner, S. M., Kennedy, E., Gonzalez, C., Stern, M. P. & Miettinen, H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes care 19, 1138–1141 (1996).
19. Goto, M. et al. Reduction in adiposity, beta-cell function, insulin sensitivity, and cardiovascular risk factors: a prospective study among Japanese with obesity. *PloS one* **8**, e57964 (2013).
20. Wu, H. Y. et al. Safety issues of long-term glucose load in patients on peritoneal dialysis—a 7-year cohort study. *PloS one* **7**, e30337 (2012).
21. Wu, H. Y. et al. Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. *Am. J. Nephrol.* **28**, 765–771 (2008).
22. Wu, H. Y. et al. Risk factors for high dialysate glucose use in PD patients—a retrospective 5-year cohort study. *Perit. Dial. Int.* **30**, 448–455 (2010).
23. Krediet, R. T. & Balafa, O. Cardiovascular risk in the peritoneal dialysis patient. *Nat. Rev. Nephrol.* **6**, 451–460 (2010).
24. Huang, J. W. et al. Osteoprotegerin, inflammation and dyslipidemia are associated with abdominal aortic calcification in non-diabetic patients on peritoneal dialysis. *Nutr. Metab. Cardiovasc. Dis.* **24**, 236–242 (2014).
25. Dobiasova, M. & Frohlich, J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). *Clin. Biochem.* **34**, 583–588 (2001).
26. Iwasa, M. et al. Visceral fat volume predicts new-onset type 2 diabetes in patients with chronic hepatitis C. *Diabetes Res. Clin. Pract.* **94**, 468–470 (2011).
27. Mori, Y., Hoshino, K., Yokota, K., Yokose, T. & Tajima, N. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. *Exp. Clin. Endocrinol. Diabetes* **113**, 334–339 (2005).
28. Konstantinou, D. M., Chatzizisis, Y. S., Louridas, G. E., Parcharidis, G. E. & Giannoglou, G. D. Non-diabetic hyperglycaemia correlates with angiographic coronary artery disease prevalence and severity. *Diabetes Metab.* **36**, 402–408 (2010).
29. Krediet, R. T. & Balafa, O. Cardiovascular risk in the peritoneal dialysis patient. *Nat. Rev. Nephrol.* **6**, 451–460 (2010).
30. Fouque, D. et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int.* **73**, 391–398 (2008).
31. de Moraes, T. P., Fortes, P. C., Ribeiro, S. C., Riella, M. C. & Pecoits-Filho, R. Comparative analysis of lipid and glucose metabolism biomarkers in non-diabetic hemodialysis and peritoneal dialysis patients. *J. Bras. Nefrol.* **33**, 173–179 (2011).
32. Unnikrishnan, R., Anjana, R. M. & Mohan, V. Drugs affecting HbA1c levels. *Indian J Endocrinol. Metab.* **16**, 528–531 (2012).

**Acknowledgements**

The study is supported by the grant of NTUH 103-S2370. The authors thank the radiologists Chung-Yi Yang and Kao-Lang Liu (Department of Medical Imaging, National Taiwan University Hospital) for reviewing the imaging of abdominal computed tomography scan.

**Author Contributions**

L.H. drafted the manuscript and performed parts of the statistical analysis. C.Y. helped the design of the study. C.T.C. and C.K.C. participated in the acquisition of data and the coordination of study. J.H. conceived of the study, and was the principal investigator for its design, coordination, and statistical analysis. K.H. made contributions in conceiving of the research. All authors read and approved the final manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Ho, L.-c. et al. Visceral fat area is associated with HbA1c but not dialysate-related glucose load in nondiabetic PD patients. *Sci. Rep.* **5**, 12811; doi: 10.1038/srep12811 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/